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Abstract
Background We analyzed perioperative platelet counts as
a potential clinical marker for survival after transthoracic
en bloc resection for esophageal cancer. Recent data
described preoperative thrombocytosis in malignancies to
be associated with poor prognosis.
Methods A retrospective analysis from a prospective
database (1997–2006) was performed for 291 consecutive
patients with esophageal cancer who underwent transtho-
racic en bloc esophagectomy and extended lymphadenec-
tomy. Squamous cell cancer was found in 47.0% and
adenocarcinoma in 50.9% (2.1% had rare histologies).
Neoadjuvant chemoradiation was performed in 152 (52%)
patients. Platelet counts before surgery and on postopera-
tive days (PODs) 1, 10, and 30 were evaluated. We used
the published cutoff value of 293 9 109/l (mean of 80
healthy controls ± standard deviation) for platelet counts.
Results High platelet counts before surgery missed sig-
nificance for poorer survival (p = 0.054). Following a
perioperative fall in thrombocytes, a significant rise at POD
10 after surgery was evident. Platelet counts of more than
293 9 109/l at this time correlated with a significantly
improved survival rate (p = 0.027). Patients with no
increase in thrombocytes until POD 10 had significantly
poorer survival (p = 0.012). Multivariate analysis
confirmed that a thrombocyte increase between the pre-
operative count and that on POD 10 is an independent
prognostic indicator (p = 0.035) for patients with com-
pletely (R0) resected tumors.
Conclusions An increase in platelet counts measured on
POD 10 following transthoracic en bloc esophagectomy
and extended lymphadenectomy is an independent prog-
nostic indicator for improved survival in patients with
esophageal cancer.
Introduction
Platelets contribute to cancer metastasis through promotion
of tumor cell proliferation; they enhance tumor cell
extravasation by potentiating tumor cell-induced endothe-
lial cell retraction and enhance tumor cell adhesion and
spreading on extracellular matrix [1].
Thrombocytes also play an important role in surgical
wound healing. Futami et al. found platelets to be a
potential source of increased serum vascular endothelial
growth factor (VEGF) levels after major surgical injury [2].
They also produce another potent angiogenetic factor,
thymidine phosphorylase (dThdPase), previously known as
platelet-derived endothelial cell growth factor. It stimulates
endothelial cell growth and chemotaxis in vitro and angi-
ogenesis in vivo [3]. Interestingly, dThdPase expression is
evident in multiple cancer cells, such as esophageal squa-
mous cell carcinoma, with correlation to tumor size, depth
of invasion, lymph node status, and tumor stage [4]. In
linear regression analyses, dThdPase expression in esoph-
ageal carcinoma correlates with microvessel density, indi-
cating its importance for neoangiogenesis.
Thrombocytosis has been found in several malignancies,
including 21% of patients with esophageal squamous cell
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carcinoma [5]. Several studies described thrombocytosis to
be associated with poor prognosis [5–8].
Our study focused on platelet counts before surgery and
at days 1, 10, and 30 after operation for being a potential
clinical marker for survival after transthoracic en bloc
resection and extended lymphadenectomy for esophageal
cancer.
Materials and methods
Patients
A retrospective study from a prospective database was
performed in 305 patients who underwent transthoracic en
bloc esophagectomy between January 1997 and October
2006 in the Department of General, Visceral and Cancer
Surgery, University of Cologne, Germany. To exclude the
effects of surgery-related postoperative complications, 14
patients (4.8%) dying within 90 days after the operation
were excluded. Among the remaining 291 study patients,
there were 234 men (80.4%) and 57 women (19.6%) with a
median age of 62 years (range 18.9–83.2 years).
Histopathologic examination of the resected specimens
revealed squamous cell cancer in 137 patients (47%),
adenocarcinoma in 148 cases (50.9%), and other, rare
entities in 6 patients (2.1%). Staging was performed
according to the 6th edition of the UICC/AJCC TNM
classification system.
Due to locally advanced diseases (cT3/4), 152 patients
(52.2%) underwent standardized neoadjuvant chemoradia-
tion as described in detail elsewhere [9] and 139 (47.8%)
did not. At 4–5 weeks after completion of chemoradiation,
transthoracic en bloc esophagectomy with two-field lym-
phadenectomy was performed. Histomorphologic regres-
sion was categorized based on the percentage of vital
residual tumor cells [9]. The relevant clinical and histo-
pathologic data are summarized in Table 1.
A time period of 30 days after operation was chosen for
the analysis of platelet counts. An automated complete
blood count was routinely obtained before surgery (pre-
operative) and at postoperative day 1 (POD1), POD10, and
POD 30. Within this time period, 287 patients (98.6%) got
no platelet transfusion, three patients received one unit, and
one patient two units of thrombocytes. Fresh frozen plasma
was administered to 86 patients (29.6%). Blood transfu-
sions were given to 185 patients (63.6%), and 106 patients
(36.4%) received no transfusion. The decision for trans-
fusion was made by the attending physician––surgeon,
anesthesiologist, intensive care unit (ICU) staff––for vari-
ous reasons. Most blood products were given during
and within the first 2 days after the operation to improve
the cardiovascular situation and to minimize the use of
catecholamines to protect the anastomosis. Unfortunately,
during the 1990s and early 2000s, blood products were
given liberally without defined criteria (e.g., hematocrit
\25%). With increasing knowledge about the risks of
immunomodulation, transfusion criteria were defined.
Indeed, over the described time period (1997–2006), a
tendency for restrained use of blood products was clearly
seen [10].
Statistical analysis
Platelet counts followed Gaussian normal distribution.
Therefore, a paired-samples t-test was chosen for analyzing
values preoperatively and at POD1, POD10, and POD30
as well as differences between preoperative values and
POD1 (DPOD1), preoperatively and POD10 (DPOD10), or
Table 1 Patient characteristics (n = 291)
Parameter No. of patients (%)
Age (years), median and range 62 (18.9–83.2)
Sex
Male 234 (80.4%)
Female 57 (19.6%)
Histology
SCC 137 (47%)
AC 148 (50.9%)
Other 6 (2.1%)
Neoadjuvant treatment
No 139 (47.8%)
Yes 152 (52.2%)
T category
pT0/ypT0 27 (9.3%)
pT1/ypT1 68 (23.4%)
pT2/ypT2 58 (19.9%)
pT3/ypT3 136 (46.7%)
pT4/ypT4 2 (0.7%)
N category
pN0/ypN0 149 (51.2%)
pN1/ypN1 142 (48.8%)
M category
cpM0/ycpM0 249 (85.6%)
cpM1aycpM1a 42 (14.4%)
Grade
G1 5 (1.7%)
G2 145 (49.8%)
G3 138 (47.4%)
G4 3 (1%)
SCC squamous cell carcinoma, AC adenocarcinoma, pT local inva-
siveness, pN lymph node metastases, c/pM distant metastases, y
neoadjuvant therapy (all according to the UICC TNM classification,
6th edition)
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preoperatively and POD30 (DPOD30). Platelet counts of
patients with or without neoadjuvant treatment and with or
without blood transfusion were compared by independent-
samples t-test. To evaluate associations of platelet values
with histopathologic parameters or transfusions, Mann–
Whitney testing was performed.
The median follow-up of the patients was 4.9 years
(range 1.1–11.0 years). All living patients had a follow-up
of more than 12 months. Currently, 133 patients are alive,
and 158 died of cancer-related causes.
Based on Shimada et al., we used the cutoff value of 293 9
109/l (mean of 80 healthy controls ± SD) for thrombocytes
[5]. Differences between platelet counts before surgery and at
1, 10, and 30 days after operation (DPOD1, DPOD10,
DPOD30) were calculated and dichotomized for positive or
negative changes.
Kaplan–Meier plots were used to describe survival dis-
tribution [11]. The log-rank test was applied to evaluate for
survival differences [12]. In addition, 95% confidence
intervals (95% CI) for the various survival curves were
calculated. The multivariate analysis of survival rates used
Cox regression analysis to identify independent prognostic
variables.
The level of significance was set at p \ 0.05. All sta-
tistical tests were calculated using the Software Package
SPSS for Windows, version 16.0 (SPSS, Chicago, IL,
USA).
Results
Platelet counts
The platelet counts distribution before surgery and at PODs
1, 10, and 30 is shown in Fig. 1. The paired-samples t-test
showed a significant rise in the platelet counts up to 30 days
after resection (p \ 0.001). It further revealed a significant
fall between the preoperative and POD1 counts (p \ 0.001),
but also a strong reactive rise between POD1 and POD10
(p \ 0.001) with a slight but not significant fall (p = 0.786)
up to day 30. There was no association between platelet
counts before operation and the (y)pT-, (y)pN-, and (y)c/pM
categories or neoadjuvant treatment; but there was a signif-
icant association with histology (p = 0.001). Differences in
thrombocyte values and correlation with clinicopathologic
parameters are listed in Table 2.
Influence of neoadjuvant therapy on perioperative
platelet counts
Thrombocyte values of patients with or without neoadju-
vant therapy are summarized in Table 3. The independent-
samples t-test revealed no significant differences.
Influence of platelet counts, fresh frozen plasma,
or blood transfusions on platelet counts
Transfusion of platelet counts had no statistically signifi-
cant influence on thrombocyte values; however, only 1.3%
of the patients received platelet transfusions. Administra-
tion of fresh frozen plasma also had no statistical influence
on platelet counts before operation or on POD1, POD10,
and POD30. This is in contrast to blood transfusion with a
significant difference between the preoperative (p = 0.016)
and POD10 counts (p = 0.030), as shown in detail in
Table 4.
A significant difference between the preoperative value
and that on POD1 (DPOD1) between patients receiving
blood or not (with blood transfusion -65 ± 101 vs.
-26 ± 65 without transfusion, p \ 0.001) was observed.
The DPOD10 platelet counts were 135 ± 160 for trans-
fused patients and 193 ± 119 for nontransfused patients
(p = 0.001); the DPOD30 values were 117 ± 143 for the
transfused ones and 178 ± 203 for nontransfused patients
(p = 0.353).
Correlation between perioperative platelet counts
and survival rates
Based on data by Shimada et al., platelet counts were
dichotomized by use of a cutoff level of 293 9 109/l [5].
There was a strong tendency but no significant difference
in survival when analyzing platelet counts from all patients
before operation (log rank, p = 0.054). The median sur-
vival rate was 3.2 ± 0.5 years for patients with lowered
Fig. 1 Box plots showing platelet counts (all counts are 9 109 per
liter) of 291 patients with transthoracic en bloc resection for
esophageal cancer before operation (267 ± 86) and on postoperative
day 1 (POD1) (216 ± 85), POD10 (421 ± 149), and POD30
(393 ± 164)
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platelet counts versus 2.0 ± 0.7 years for the group with
increased counts.
The day after operation, no significant difference in
survival was obvious (p = 0.890). Interestingly, however,
patients with lower platelet counts had a comparatively
shorter median survival (2.4 ± 0.3 vs. 3.2 ± 0.9 years).
A significant survival benefit, however, was achieved on
POD10 for patients with increased thrombocytes (p =
0.027) (Fig. 2). The median survival was 1.8 ± 0.3 years for
patients with lowered platelet counts and 3.0 ± 0.4 years for
the elevated group. At POD 30, again there was no difference
in survival (p = 0.546), and the median survival was
2.4 ± 0.5 vs. 3.2 ± 0.5 years.
Perioperative increase of thrombocytes and survival
To determine whether there was a high number of platelets
themselves or a postoperative reactive increase differences
in platelet counts between the preoperative and POD1
(DPOD1), POD10 (DPOD10), and POD30 (DPOD30) were
calculated. For detailed data see Table 5.
Platelet differences were dichotomized for cases[0 and
B0. DPOD1 revealed a nearly significant survival benefit
for patients with platelet increase (median survival
Table 2 Platelet counts in
correlation to clinicopathologic
parameters
All platelet counts are the
number of platelets 9109 per
liter
Ø, average value; DPOD10,
difference on postoperative day
10
Parameter Preoperative
(Ø ± SD)
Count p DPOD10
(Ø ± SD)
p
Histology 0.001* 0.025*
SCC 283 ± 89 142 ± 156
AC 252 ± 82 175 ± 141
T category 0.294 0.377
(y)pT0 272 ± 91 129 ± 144
(y)pT1 267 ± 77 174 ± 146
(y)pT2 252 ± 87 144 ± 129
(y)pT3 271 ± 89 159 ± 158
(y)pT4 463 4
N category 0.231 0.013*
(y)pN0 259 ± 82 175 ± 135
(y)pN1 275 ± 90 136 ± 160
M category 0.825 0.057
(y)c/pM0 268 ± 89 163 ± 151
(y)c/pM1 263 ± 70 118 ± 128
Neoadjuvant
treatment
0.489 0.667
No 263 ± 78 151 ± 143
Yes 269 ± 91 166 ± 149
Table 3 Perioperative platelet counts with and without neoadjuvant
chemoradiation
Platelet count (9 109/l)
Parameter Preoperative POD1 POD10 POD30
Without neoadjuvant treatment
No. of patients 136 136 138 45
Ø ± SD 263 ± 78 218 ± 59 413 ± 138 393 ± 165
SCC 280 ± 85 217 ± 59 416 ± 152 428 ± 171
AC 247 ± 68 216 ± 56 416 ± 130 363 ± 161
With neoadjuvant treatment
No. of patients 145 147 148 53
Ø ± SD 271 ± 94 214 ± 104 429 ± 159 393 ± 165
SCC 284 ± 92 209 ± 72 423 ± 163 388 ± 126
AC 257 ± 95 223 ± 132 439 ± 156 411 ± 219
p 0.534 0.666 0.414 0.628
Table 4 Perioperative platelet counts with and without blood
transfusion
Platelet count (9109/l)
Parameter Preoperative POD1 POD10 POD30
Without blood transfusion
No. of patients 102 105 106 14
Ø ± SD 251 ± 75 226 ± 72 445 ± 136 430 ± 229
With blood transfusion
No. of patients 179 178 180 84
Ø ± SD 276 ± 91 210 ± 92 407 ± 156 386 ± 151
p 0.016* 0.117 0.030* 0.508
* significance is achieved
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2.33 ± 0.35 vs. 4.69 ± 1.53, p = 0.051). Analysis of
DPOD10 however, showed a clearly significant result (p =
0.012). The median survival was 1.0 ± 0.3 years (without
increase) vs. 3.0 ± 0.4 years for patients with a positive
difference in platelet counts (Fig. 3). This is in contrast to
DPOD30 (1.11 ± 0.86 vs. 3.24 ± 0.33, p = 0.392).
Subgroup univariate analysis of patients with neoadju-
vant treatment (Table 6) and without neoadjuvant treat-
ment (Table 7) showed no significant survival advantage in
the neoadjuvant chemoradiation group for increased or
decreased platelet counts. On the other hand, in the group
of the nonneoadjuvant-treated patients, DPOD1 and
DPOD10 [0 were associated with significantly better sur-
vival (p = 0.015 and p = 0.02, respectively).
Multivariate survival analysis
Multivariate analysis for all R0-resected patients was per-
formed including the following parameters: (y)pT, (y)pN,
and (y)c/pM categories, histopathologic response to neo-
adjuvant therapy, blood transfusion, fresh frozen plasma
(FFP) transfusion, platelet transfusion, and platelet counts
preoperatively and at POD10 as well as DPOD10. Signif-
icance was obtained for: (y)pT [p \ 0.001 for stage T1 vs.
T2, the hazard ratio (HR) and 95% CI (in parentheses) were
1.99 (0.81–4.91) and for T1 vs. T3 they were 3.89 (2.01–
7.50)]; (y)pN [p \ 0.001, HR 2.27 (1.57–3.29)]; (y)c/pM
[p = 0.040, HR 1.56 (1.02–2.39)]; and DPOD10 [p =
0.035, HR 0.60 (0.37–0.97)].
Fig. 2 Kaplan-Meier survival curves for patients undergoing trans-
thoracic en bloc resection for esophageal cancer classified by platelet
counts of [293 9 109/l and B293 9 109/l on POD10 (p = 0.027)
Table 5 Perioperative differences in absolute platelet counts
Parameter DPOD1 DPOD10 DPOD30
No. of patients 274 277 91
Ø ± SD -50 ± 91 156 ± 149 124 ± 152
Dichotomized data (B0 vs. [0)
Number
B0 217 (79.2%) 32 (11.6%) 19 (20.9%)
[0 57 (20.8%) 245 (88.4%) 72 (79.1%)
Median survival
B0 2.33 ± 0.35 1.00 ± 0.30 1.11 ± 0.86
[0 4.69 ± 1.53 3.00 ± 0.38 3.24 ± 0.33
p 0.051 0.012* 0.392
* significance is achieved
Fig. 3 Kaplan-Meier survival curves of patients undergoing trans-
thoracic en bloc resection for esophageal cancer classified by the
existence of a thrombocyte increase between preoperative values and
POD10 (p = 0.012)
Table 6 Perioperative differences in absolute platelet counts for
patients with neoadjuvant treatment
Parameter DPOD1 DPOD10 DPOD30
No. of patients 139 140 46
Ø ± SD -54 ± 106 166 ± 149 135 ± 148
Dichotomized data (B0 vs. [0)
Number
B0 110 (79.1%) 13 (9.3%) 9 (19.6%)
[0 29 (20.9%) 127 (90.7%) 37 (80.4%)
Median survival
B0 1.96 ± 0.23 1.52 ± 0.61 1.11 ± 0.46
[0 2.30 ± 0.17 2.25 ± 0.22 2.34 ± 0.24
p 0.904 0.195 0.289
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Subgroup analysis in patients without neoadjuvant
therapy showed significance for pT (p = 0.008), pT1 vs.
pT2 [HR 1.63 (0.63–4.20)], and pT1 vs. pT3 [HR 3.1
(1.42–6.80]; for pN [p = 0.011, HR 2.40 (1.22-4.81)]; and
blood transfusion (no or yes) [p = 0.059, HR 1.81 (0.98–
3.35)].
In cases with neoadjuvant chemoradiation, significance
could be shown for pN0 vs. pN1 [p \ 0.001, HR 2.42
(1.49–3.93)] and POD10 [p = 0.009, HR 0.52 (0.32–
0.85)]. For a minor versus major response, there was a
strong tendency that just missed significance [p = 0.056,
HR 0.61 (0.37–1.01)].
Discussion
In patients with esophageal cancers who underwent trans-
thoracic en bloc esophagectomy with extended abdominal
and mediastinal (two-field) lymphadenectomy, platelet
counts showed, following an initial fall, a significant rise at
POD 10 and partial normalization at POD30. This obser-
vation is in line with data from Spence et al., who dem-
onstrated elevated amounts of platelet counts on POD 10
with return to preoperative levels by 6 weeks [13].
In a previous report, Shimada and coworkers reported
a preoperative platelet count of more than 293 9 109/l to
be associated with tumor progression and poor survival in
patients with squamous cell carcinoma of the esophagus
[5]. In our population, this result could be confirmed as a
tendency but just missed significance (p = 0.054). This
might have been influenced by our mixed population,
with 47% squamous cell carcinomas and 51% adenocar-
cinoma of the esophagus. Subgroup analysis showed
higher platelet counts preoperatively in patients with
squamous cell cancer than in those with adenocarcinoma,
with switched postoperative (data not shown). Based on
the presented data, both values could be seen as a
predictor for a poorer prognostic outcome in patients with
SCC [5].
This tendency of a survival disadvantage with preopera-
tively elevated platelet counts, however, switched com-
pletely into a highly significant survival benefit 10 days after
resection. Furthermore, the increase between the preopera-
tive and POD10 counts (DPOD10) indicated a significant
survival advantage. Multivariate analysis confirmed
DPOD10 as an independent prognostic factor next to the
(y)pT, (y)pN, and (y)c/pM categories. These results have not
been published yet to the best of our knowledge.
We hypothesize that the bone marrow is stimulated due to
surgical stress and produces and/or releases higher amounts
of thrombocytes. In the literature, major surgery (esopha-
gectomy) caused a twofold increase of VEGF compared to
laparoscopic cholecystectomy (minor surgery). Maximum
VEGF levels correlated with maximum platelet counts in the
study by Futami et al. [2]. Although exact mechanisms of
platelet production stimulation are largely unknown, inter-
actions with cytokines in a systemic inflammatory reaction
are discussed [14]. Interleukin-6 (IL-6) was shown to support
megakaryocytic proliferation and differentiation in megak-
aryocytopoiesis [15]. Perioperative administration of ste-
roids was reported to reduce postoperative serum IL-6 levels
caused by surgical stress [16].
Furthermore, restriction through the malignant tumor or
damage to the bone marrow through chemotherapeutic
agents or irradiation appears possible. Especially, the
S-phase-specific agent 5-fluorouracil is known to inhibit
DNA synthesis in continuous intravenous infusion [17];
and myelosuppresion is sometimes observed [18]. Suwa
et al. supposed that the normal bone marrow response of
releasing band cells from the postmitotic marrow pool after
surgery is disturbed by neoadjuvant therapy. Because of
missing differences in white blood cell and neutrophil
counts, this marrow response was not predictable until
surgery was performed [19]. This is in line with our data
showing no difference in platelet counts between patients
undergoing chemoradiation and those who did not.
In contrast, univariate analysis of the differences
between preoperative values and POD1, POD10, and
POD30 (DPOD1, 10, or 30) showed a significant survival
advantage for increasing values in the nonpretreated sub-
group. No significant survival benefit could be detected in
the neoadjuvant treated subgroup. In the multivariate sub-
group analysis, the nonpretreated group showed pT, pN,
and blood transfusion categories as significant factors,
whereas in the neoadjuvant-treated subgroup ypN, histo-
pathologic response category, and POD10 showed signifi-
cance. These data are difficult to interpret and further
studies are necessary to clarify this issue.
Interestingly, transfusion of FFP had no statistical
influence on platelet counts or in the multivariate survival
Table 7 Perioperative differences in absolute platelet counts for
patients without neoadjuvant treatment
Parameter DPOD1 DPOD10 DPOD30
No. of patients 133 135 44
Ø ± SD -45 ± 70 150 ± 142 115 ± 157
Dichotomized data (B0 versus [0):
Number
B0 105 (78.9%) 18 (13.3%) 10 (22.7%)
[0 28 (21.1%) 117 (86.7%) 34 (77.3%)
Median survival
B0 3.07 ± 0.46 0.60 ± 0.34 0.67
[0 6.2 ± 1.38 6.3
p 0.015* 0.02 * 0.46
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analysis. The small number of patients receiving platelets
(1.4%) allows no conclusions but clearly eliminates its
influence on our data. This is in contrast to blood transfu-
sions, where higher platelet counts before the resection and
a lower value after surgery were detected. Even differences
between preoperative and postoperative data were less in
comparison to nontransfused patients. Based on the avail-
able data, including our recently published series [10],
transfused patients are at higher risk for reduced survival.
We cannot absolutely rule out a potential reciprocal
dependence, however, by multivariate analysis as only
differences in platelet counts (DPOD10) and not blood
transfusion categories achieved significance. Therefore,
perioperative platelet counts appear to be an interesting
prognostic parameter that is easy to obtain.
Interestingly, absolute platelet counts seem to be inde-
pendent of perioperative complications. Futami and
coworkers found that postoperative inflammatory lung
complications led to significantly increased serum VEGF
levels but did not influence platelet counts. They suggested
that inflammatory cells are an additional source of VEGF
[2].
Conclusions
We demonstrate a significant perioperative fall of throm-
bocytes followed by a highly significant rise on POD10
after transthoracic en bloc esophagectomy and extended
lymphadenectomy for esophageal cancer. An increase
between preoperative platelet counts and values 10 days
after resection is an independent good prognostic factor for
patients with esophageal cancer. Further studies are nec-
essary to elucidate whether differences in platelet counts
are a surrogate marker or if they indeed have a pathoge-
netic impact.
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